Monday, 10 Dec 2018

You are here

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Most rheumatologists are very comfortable using methotrexate, but many of our patients have concerns about side effects – especially where liver toxicity is concerned. Research presented by a group from Reading, UK (Abstract SAT0215) should go a long way to help us to reassure them.  The group monitored liver function tests in 1964 rheumatology patients over the course of 13 months. The patient cohort included a mix of patients with RA, PsA, and AS) of whom 775 were taking one concomitant DMARD, 82 were on triple therapy and 396 on a biologic alongside their methotrexate. 

Whereas 2.4% of patients developed an elevated ALT (35-100U/l), only 0.51% (10 patients) developed an ALT >100 U/l. Abnormalities were persistent in 8 of these patients but only resulted in one patient in the cohort discontinuing their methotrexate. Although the reported incidence of ALT abnormalities is a bit lower than that in the published literature (some data on doses of methotrexate used in the cohort would also have been useful) this is good news and echoes  the feeling amongst most rheumatologists that this drug is mostly safe where the liver is concerned The authors also suggest that based on this data, that the current BSR guidelines (which suggest monitoring each 3 months on patients on stable doses of methotrexate) are appropriate.

SC safer than Oral Methotrexate

Most rheumatologists are increasingly comfortable with the use of injectable methotrexate. It certainly appears to be better absorbed and more effective than oral methotrexate a group of researchers from the UK propose that it may be safer too (Abstract SAT0235). Using an online safety monitoring tool, FBC and LFT results were monitored from 8394 patients since 

Whereas the mean dose of MTX used in those on sc dosing was higher (21mg vs 17mg, range 5-40mg) the difference in incidence of LFT abnormalities (ALT > 80 U/l) between the two groups was not statistically significant. Patients on injectable methotrexate however (151/949) were less likely to develop neutropenia than those on oral methotrexate (491/2093) (p <0.00001 sc vs oral). Whereas the liver toxicity data is a little underwhelming, sc methotrexate may well be safer where neutropenias are concerned.

The online monitoring tool used in the study, TA Monitor, was developed by a rheumatologist (http://www.therapyaudit.com/tamonitor/) and allows web based monitoring of adverse events to medications like methotrexate. Another thing that caught my eye in that study as the dose range (up to 40mg) of Methotrexate used.

50mg of sc Methotrexate appears well tolerated

A group of Italian and US researchers have been evaluating the tolerability and safety of higher does of sc Methotrexate in RA (Abstract SAT0228). Their study protocol was an open labelled pilot study of 12 weeks duration, where 9 patients with RA were treated initially with a dose of 50mg of sc methotrexate for 4 weeks, followed by 25mg weekly for 4 weeks and the 15mg weekly for 4 weeks. Overall these higher doses were well tolerated with only AE’s occurring in 4 patients, none of which were severe. One patient developed an ALT (<2 ULN) which resolved spontaneously (the same patient also developed vertigo and subsequently withdrew). One patient developed a UTI, another short lived low back pain which resolved, and one patient developed fatigue. 

Although the numbers are small and study duration short, it will be interesting to see if this regimen proves more effective than traditionally used methotrexate doses in RA.

Add new comment

More Like This

Trazodone High Risk of Falls and Fractures

The CMAJ (Canadian Medical Association Journal) has reported that trazadone use in the elderly may be associated with a risk of falls and major fractures. 

Using claims data from ICES, researchers compared 6588 seniors given trazadone to 2875 receiving another atypical antipsychotic.

Musculoskeletal Events with Statin Use

Analysis of the FDA Adverse Event Reporting System data examined the association between statins' musculoskeletal adverse events (MAEs).

Review of the data shows that atorvastatin and rosuvastatin (with strong low‐density lipoprotein cholesterol‐lowering effects) had a higher risk and a faster onset of MAEs when compared with simvastatin.

They could not detect whether concomitant drugs shifted the onset timing of MAEs. 

Low Short-Term Risks of NSAIDs in High Risk Patients

JAMA has published a large Canadian claims-based study showing that nonsteroidal anti-inflammatory drug (NSAID) use in patients with hypertension, heart failure, or chronic kidney disease was not associated with a significant safety risk - but this only looked at short-term outcomes (7-37 days of exposure). 

Update on Checkpoint Inhibitor Safety

“Autoimmunity is the Achilles heel of onco-immunotherapy” per Dr. Leonard Calabrese, which leaves a dilemma for rheumatologists. Onco-immunotherapy induces immune dysregulation to allow patients to develop an immune response to their cancer cells. An unfortunate side effect for patients taking onco-immunotherapy is often autoimmune-like diseases referred to as immune adverse reactions (irAEs). Studies in France and the United States have shown that irAEs can be a good prognostic sign, suggesting these therapies are working. Rheumatology is faced with new problems as onco-immunotherapies may induce new chronic diseases in multiple different forms secondary to the treatment.

Anti-phospholipid Antibodies and Myocardial Infarction.

The Annals of Internal Medicine features a communique from the Karolinska Institutet in Sweden demonstrating that elevated levels of antiphospholipid antibodies may be found in patients with myocardial infarction without any autoimmune co-morbidity, published in Annals of Internal Medicine reports.